Browse SP1

Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Nuclear location is governed by glycosylated/phosphorylated states. Insulin promotes nuclear location, while glucagon favors cytoplasmic location.
Domain -
Function

Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Binds also the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression. Isoform 3 is a stronger activator of transcription than isoform 1. Positively regulates the transcription of the core clock component ARNTL/BMAL1 (PubMed:10391891, PubMed:11371615, PubMed:11904305, PubMed:14593115, PubMed:16377629, PubMed:16478997, PubMed:16943418, PubMed:17049555, PubMed:18171990, PubMed:18199680, PubMed:18239466, PubMed:18513490, PubMed:18619531, PubMed:19193796, PubMed:20091743, PubMed:21798247). Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays a role in protecting cells against oxidative stress following brain injury by regulating the expression of RNF112 (By similarity).

> Gene Ontology
 
Biological Process GO:0006790 sulfur compound metabolic process
GO:0009301 snRNA transcription
GO:0016073 snRNA metabolic process
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0035821 modification of morphology or physiology of other organism
GO:0036166 phenotypic switching
GO:0042762 regulation of sulfur metabolic process
GO:0042795 snRNA transcription from RNA polymerase II promoter
GO:0043434 response to peptide hormone
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0043921 modulation by host of viral transcription
GO:0043923 positive regulation by host of viral transcription
GO:0044033 multi-organism metabolic process
GO:0044272 sulfur compound biosynthetic process
GO:0046782 regulation of viral transcription
GO:0048511 rhythmic process
GO:0048524 positive regulation of viral process
GO:0050434 positive regulation of viral transcription
GO:0050792 regulation of viral process
GO:0051176 positive regulation of sulfur metabolic process
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0052312 modulation of transcription in other organism involved in symbiotic interaction
GO:0052472 modulation by host of symbiont transcription
GO:0070813 hydrogen sulfide metabolic process
GO:0070814 hydrogen sulfide biosynthetic process
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0098781 ncRNA transcription
GO:0100057 regulation of phenotypic switching by transcription from RNA polymerase II promoter
GO:1900239 regulation of phenotypic switching
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
GO:1904826 regulation of hydrogen sulfide biosynthetic process
GO:1904828 positive regulation of hydrogen sulfide biosynthetic process
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001103 RNA polymerase II repressing transcription factor binding
GO:0001159 core promoter proximal region DNA binding
GO:0008022 protein C-terminus binding
GO:0008134 transcription factor binding
GO:0035035 histone acetyltransferase binding
GO:0042826 histone deacetylase binding
GO:0043425 bHLH transcription factor binding
GO:0070491 repressing transcription factor binding
GO:0071837 HMG box domain binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0032993 protein-DNA complex
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG hsa04350 TGF-beta signaling pathway
hsa04915 Estrogen signaling pathway
Reactome R-HSA-2426168: Activation of gene expression by SREBF (SREBP)
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-2559585: Oncogene Induced Senescence
R-HSA-1989781: PPARA activates gene expression
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
R-HSA-1655829: Regulation of cholesterol biosynthesis by SREBP (SREBF)
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-2173796: SMAD2/SMAD3
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SP1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28574228CholangiocarcinomaInhibit immunityP-Sp1 also regulated aPKC-ι/Snail-induced EMT-like changes and immunosuppression in CCA cells.
23509364Breast Carcinoma; Hepatocellular Carcinoma; Colorectal CarcinomaPromote immunityOverexpression of Snail1 and inhibition of glycogen synthase kinase-3β in colorectal tumor cells markedly induced the activity of Sp1 transcription factor, which plays a key role in the upregulation of NKG2DL expression during EMT.
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.7 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0060.977
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1270.944
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0820.95
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1990.58
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1660.943
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.660.822
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1180.771
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2340.904
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0080.997
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.810.564
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3360.523
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0220.722
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSP1
NameSp1 transcription factor
Aliases specificity protein 1; Transcription factor Sp1
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.